Drug Trial Radar · NCT00792298
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
254
Actual
Start
Nov 5, 2008
Primary completion
Dec 26, 2009
Study completion Dec 26, 2009
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A cross-over, polysomnography study to test the safety, tolerability and effectiveness of different doses of suvorexant (MK-4305) in the treatment of patients with primary insomnia.
Conditions
- Primary Insomnia
Interventions
SuvorexantDrug
oral tablet taken before bedtime
Dose-matched Placebo to SuvorexantDrug
Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
Primary outcomes
What the sponsor says the trial is designed to measure.
- LS Mean Sleep Efficiency (SE) During Periods 1 and 2Time frame: Night 1 and end of Week 4
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.